Myrexis, Inc. MYRX today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa as a front-line treatment for glioblastoma multiforme.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
